A new drug, currently known as GBT440, shows promise in preventing red blood cells from sickling, as well as reducing hemolysis (where red blood cells rupture) and improving anaemia. This study is quite early into the research process,and the results of this first trial suggest further investigation is necessary.

These results will be presented at ASH–the American Society of Hematology–Annual Meeting and Exposition in December this year.

Read more about the study here.